Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04521621
Title A Study of V937 in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors (V937-013)
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Merck Sharp & Dohme Corp.
Indications

gastric adenocarcinoma

hypopharynx cancer

hepatocellular carcinoma

laryngeal squamous cell carcinoma

Advanced Solid Tumor

oropharynx cancer

gastroesophageal junction adenocarcinoma

head and neck squamous cell carcinoma

triple-receptor negative breast cancer

skin squamous cell carcinoma

oral squamous cell carcinoma

Therapies

Coxsackievirus A21 + Pembrolizumab

Age Groups: adult | senior
Covered Countries USA | CAN


No variant requirements are available.